SCHEMBL508763

SCHEMBL508763

O=[N+]([O-])c1ccc(CBr)c(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.60
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 5/20 0.48
VCAM1 P19320 1/20 0.46
PDE7A Q13946 5/20 0.45
TDP1 Q9NUW8 2/20 0.44
CYP1A2 P05177 1/20 0.44
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP3A4 P08684 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4D Q08499 1/20 0.43
PDE7B Q9NP56 1/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29672035 1.00 HSD17B10 (0.60) HSD17B10KMT2AALDH1A1VCAM1PDE7A
SCHEMBL30001251 0.86 HSD17B10 (0.56) HSD17B10KMT2AALDH1A1VCAM1PDE7A
SCHEMBL2595412 0.86 HSD17B10 (0.56) HSD17B10KMT2AALDH1A1VCAM1PDE7A
SCHEMBL29906404 0.85 HSD17B10 (0.60) HSD17B10KMT2AALDH1A1VCAM1TDP1
SCHEMBL842908 0.85 HSD17B10 (0.60) HSD17B10KMT2AALDH1A1VCAM1TDP1
SCHEMBL8703100 0.83 HSD17B10 (0.46) HSD17B10KMT2AALDH1A1VCAM1PDE7A
SCHEMBL136817 0.83 CYP1A2 (0.62) KMT2AALDH1A1TDP1CYP1A2LMNA
SCHEMBL7786691 0.83 HSD17B10 (0.62) HSD17B10KMT2AALDH1A1VCAM1PDE7A
SCHEMBL868877 0.83 HSD17B10 (0.62) HSD17B10KMT2AALDH1A1VCAM1PDE7A
SCHEMBL2205749 0.83 HSD17B10 (0.62) HSD17B10KMT2AALDH1A1VCAM1PDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361232-A1 SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICALS USA INC (US) 2025-11-27 US disclosed
US-12398142-B2 Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases EMORY UNIVERSITY (US) 2025-08-26 US disclosed
CN-114573567-B Indazole cyclotriazole compound and preparation method and application thereof 西安交通大学 2023-05-02 CN disclosed
US-20220177480-A1 Abelson Non-Tyrosine Kinase Compounds for the Treatment of Neurodegenerative Diseases UNIV EMORY (US) 2022-06-09 US disclosed
US-20220177480-A1 Abelson Non-Tyrosine Kinase Compounds for the Treatment of Neurodegenerative Diseases UNIV EMORY (US) 2022-06-09 US disclosed
CN-114573567-A Indazole cyclic triazole compound and preparation method and application thereof 西安交通大学 2022-06-03 CN disclosed
US-20220081440-A1 SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS TAKEDA PHARMACEUTICALS U.S.A., INC. 2022-03-17 US disclosed
EP-3747441-A1 BICYCLIC HETEROARYL COMPOUNDS ARIAD Pharmaceuticals, Inc. (US) 2020-12-09 EP disclosed
CN-112010789-A Vinyl sulfonamide or vinyl amide compounds, and preparation method and application thereof 中国科学院上海药物研究所 2020-12-01 CN disclosed
WO-2020214999-A1 ABELSON NON-TYROSINE KINASE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES EMORY UNIVERSITY (US) 2020-10-22 WO disclosed
EP-1117659-B1 SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS WYETH CORP (US) 2003-12-03 EP disclosed
WO-2003040108-A1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2003-05-15 WO disclosed
US-6288082-B1 COMPOUNDS SUCH AS 6,7-DIETHOXY-4-(INDAN-5-YLAMINO) -QUINOLINE-3-CARBONITRILE USED AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYCSTIC KIDNEY DISEASE AMERICAN CYANAMID COMPANY 2001-09-11 US disclosed
EP-1117659-A1 SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS American Cyanamid Company (US) 2001-07-25 EP disclosed
US-6265418-B1 ANTICOAGULANTS UBE INDUSTRIES, LTD. (JP) 2001-07-24 US disclosed
CN-1265661-A N-acylamino acid amide compounds and intermediates for preparation thereof UBE INDUSTRIES (JP) 2000-09-06 CN disclosed
EP-1020467-A1 N-ACYLAMINO ACID AMIDE COMPOUNDS AND INTERMEDIATES FOR PREPARATION THEREOF UBE INDUSTRIES LIMITED (JP) 2000-07-19 EP disclosed
WO-2000018761-A1 SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS AMERICAN CYANAMID COMPANY (US) 2000-04-06 WO disclosed
US-4436751-A Nitrobenzyl monates antibacterial compounds BEECHAM GROUP LIMITED (GB) 1984-03-13 US disclosed
EP-0055616-A1 Antibacterial compounds BEECHAM GROUP PLC (GB) 1982-07-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220081440-A1 SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS MAP4K2, MAP3K19, MAP3K1 HSD17B10 3108/4885KMT2A 1337/4885ALDH1A1 980/4885
US-20220177480-A1 Abelson Non-Tyrosine Kinase Compounds for the Treatment of Neurodegenerative Diseases ABL2, ABL1, FYN HSD17B10 4283/4885KMT2A 784/4885ALDH1A1 3669/4885
US-20250361232-A1 SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS MAP4K2, MAP3K19, MAP3K1 HSD17B10 3108/4885KMT2A 1337/4885ALDH1A1 980/4885
US-12398142-B2 Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases ABL2, ABL1, FYN HSD17B10 4283/4885KMT2A 784/4885ALDH1A1 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.